NASDAQ:LQDA
Liquidia (LQDA)
Financials 
Technical Analysis 
Jul 5, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Liquidia (LQDA-Q) is a small but promising company focused on addressing pulmonary arterial hypertension (PAH), a rare lung disease. Analysts highlight that Liquidia's drug is outperforming its competitor United Therapeutics, suggesting a strategic pivot for investors. With the potential to capture market share from UT, the outlook for Liquidia appears positive. The current analyst price target stands at $53.75, indicating confidence in the company's growth trajectory. Investors previously successful with UT may find Liquidia a more favorable option, positioning it as a significant player in the PAH treatment landscape.
- «
- ‹
- 1
- ›
- »
Popular Articles
Most Recent Experts
Liquidia (LQDA) Frequently Asked Questions
What is Liquidia stock symbol?
Liquidia is a American stock, trading under the symbol LQDA (previously LQDA-Q on Stockchase) on the NASDAQ (LQDA). It is usually referred to as NASDAQ:LQDA or LQDA
Is Liquidia a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on LQDA (previously LQDA-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Liquidia.
Is Liquidia a good investment or a top pick?
Liquidia was recommended as a Top Pick by Gordon Reid on 2026-03-10. Read the latest stock experts ratings for Liquidia.
Why is Liquidia stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Liquidia.
Is Liquidia worth watching?
Liquidia is covered by Stockchase experts and is worth watching.
What is Liquidia stock price?
On 2026-07-02, Liquidia (LQDA) stock closed at a price of $78.90.
A small company involved in a rare lung disease, PAH. He made money off a similar situation in United Therapeutics, but LQDA has a better drug that is taking share from UT. So, he switched horses.
(Analysts’ price target is $53.75)